Cosmo Pharmaceuticals Achieves 104.2M Revenue and 9.5M EBITDA in 2025; Proposes 2.10 Dividend; Establishes 2026 Growth Framework
Ad hoc announcement pursuant to Art. 53 LR Full Year 2025 revenue of €104.2 million, in line with guidance, with 85% recurring revenues Recurring revenues of €88.1 million, +15% year-over-year, reflecting structural business transformation EBITDA of €9.5 million, exceeding the upper end of guidance
Soins de santé et hôpitaux, Santé
2026-03-09 2:00 AM EDT | Cosmo Pharmaceuticals N.V.
Apolo V Acquisition Corp. Announces Shareholder Approvals
Toronto, Ontario--(Newsfile Corp. - March 6, 2026) - Apolo V Acquisition Corp. (TSXV: AFV.P) ("Apolo" or the "Company"), a "capital pool company" pursuant to the policies of the TSX Venture Exchange (the "TSXV"), is pleased to announce the voting results from its Special Meeting of Shareholders (the "Apolo Meeting") held on Thursday, March 5, 2026 in connection with its previously announced proposed qualifying transaction (the "Qualifying Transaction"
Soins de santé et hôpitaux, Santé
2026-03-06 9:08 AM EST | TelyRx
Mobile-health Network Solutions and Medpod Sign MOU to Advance AI-Driven, High-Fidelity Global Healthcare
Singapore, Singapore--(Newsfile Corp. - March 6, 2026) - Mobile-health Network Solutions (NASDAQ: MNDR) ("MNDR" or the "Company"), a leading AI-powered digital health platform, and Medpod Inc., a U.S.-based innovator in high-fidelity telediagnostics software and infrastructure, today announced the signing of a Memorandum of Understanding (MOU) outlining a strategic partnership to jointly expand intelligent, clinically robust healthcare access across global markets. Under the collaborati
2026-03-06 8:52 AM EST | Mobile-health Network Solutions
Tersis Technologies Names Hugo Mijares Chief Architectural Officer, Positioning for Future Infrastructure and Energy Development in Venezuela
Brooksville, Florida--(Newsfile Corp. - March 5, 2026) - Tersis Technologies (OTCID: TERS), a systems-focused energy and infrastructure company advancing regenerative solutions through practical integration, today announced the appointment of Hugo Mijares as Chief Architectural Officer. Mijares is the founder of ONE D+B MIAMI, a multidisciplinary design studio established in 2007 and known for its focus on material exploration, technical rigor, and architectural clarity. He earned his a
Agriculture, Énergie, Énergies de substitution, Santé
2026-03-05 5:57 PM EST | Tersis Technologies Inc.
Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update
King of Prussia, Pennsylvania--(Newsfile Corp. - March 5, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeuti
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-03-05 4:05 PM EST | Phio Pharmaceuticals Corp.
Rapid Dose Therapeutics (DOSE) (RDTCF) Secures Patent for QuickStrip(TM) Nicotine Oral Film Targeting $38B Smoke-Free Nicotine Market
Burlington, Ontario--(Newsfile Corp. - March 5, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF), a Canadian biotechnology company specializing in oral thin film drug delivery technology, today announced the grant of a key patent for its QuickStrip™ Nicotine Bilayer Oral Film in partnership with Aavishkar Oral Strips. The patent, titled "Nicotine Bilayer Oral Film and Process for Preparation Thereof," has been granted by the Indian Patent Office under Patent Number
2026-03-05 10:08 AM EST | Rapid Dose Therapeutics Corp.
AliMed Launches New Line of Lightweight Hybrid Gel-Foam Positioners Aimed at Improving Safety for Patients and Staff
Dedham, Massachusetts--(Newsfile Corp. - March 5, 2026) - AliMed, LLC, a Massachusetts-based medical device manufacturer and distributor, is introducing its own line of innovative hybrid gel-foam positioners, expanding its broad portfolio of patient positioners. This unique design delivers the benefits of all-gel positioners with up to 50% reduction in weight. These new positioners are being sold under the name AliBlue™ L
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-03-05 10:00 AM EST | AliMed, LLC
BioHarvest Sciences Announces Board Transition and Appointment of Prof. Hezi Levy
British Columbia and Rehovot, Israel--(Newsfile Corp. - March 5, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology, today announced that Mr. David Tsur will step down from its Board of Directors after more than four years of service. The Company further announced the appointment of Prof. Hezi Levy to its Board of Directors, effective immediately. Mr. Tsur has served on BioHarvest's Board since 2021 and
Biotechnologies, Pharmaceutique, Santé
2026-03-05 7:30 AM EST | BioHarvest Sciences Inc.
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - March 5, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-03-05 7:00 AM EST | Phio Pharmaceuticals Corp.
Cosmo Announces Strategic R&D Collaboration to Advance AI-Based Detection of Early Neoplasia in Barrett's Esophagus
Dublin, Ireland--(Newsfile Corp. - March 5, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced a strategic Research and Development Agreement with Amsterdam UMC and Eindhoven University of Technology to develop and clinically validate an artificial intelligence (AI)-based computer-aided detection (CADe) system for the identification of early neoplasia in Barrett’s esophagus. The collaboration represents an important step in ex
Soins de santé et hôpitaux, Santé
2026-03-05 1:00 AM EST | Cosmo Pharmaceuticals N.V.
FDA Leadership Headlines at AAMI neXus 2026 Medtech Conference
Arlington, Virginia--(Newsfile Corp. - March 4, 2026) - The Association for the Advancement of Medical Instrumentation (AAMI) officially welcomes speakers from the U.S. Food and Drug Administration (FDA) to its upcoming medical device standards conference, AAMI neXus 2026. Dr. Michelle Tarver, Director of FDA's Center for Devices and Radiological Health (CDRH), w
2026-03-04 8:50 AM EST | Association for the Advancement of Medical Instrumentation
Safe Supply Confirms NIRLAB Drug Analysis Devices Actively Deployed and Under Field Evaluation by Government Stakeholders
Toronto, Ontario--(Newsfile Corp. - March 4, 2026) - Safe Supply Streaming Co Ltd. (CSE: SPLY) (OTCQB: SSPLF) (FSE: QM4) ("Safe Supply" or the "Company"), a pioneer in health, safety, and rapid response technologies, today provided an update on its NIRLAB SA ("NIRLAB") pilot program, confirming that NIRLAB NIRLIGHT spectroscopy drug analysis devices are currently deployed with government stakeholders and are being actively tested in the field. The Company is also reportin
2026-03-04 7:07 AM EST | Altrova Health Inc.
Numinus Wellness Advises of a Change of Auditor
Vancouver, British Columbia--(Newsfile Corp. - March 3, 2026) - Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is advising of a change of its auditor. The Company's previous auditor, Horizon Assurance LLP ("Horizon") no longer serves as the Company's auditor, with PKF Antares Professional Corpora
2026-03-03 5:00 PM EST | Numinus Wellness Inc.
Adia Nutrition Announces Submission of Final Revised Protocol for Lower Back Pain Study with AdiaVita
Winter Park, Florida--(Newsfile Corp. - March 3, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a company focused on regenerative medicine and therapeutic solutions, today announced that its subsidiary, Adia Med of Winter Park, LLC, has submitted its final revised protocol to the Institutional Review Board (IRB) for the lower back pain clinical study.
Soins de santé et hôpitaux, Santé
2026-03-03 10:20 AM EST | Adia Nutrition Inc.
Canadian Pulmonary Fibrosis Foundation: Oxygen Therapy Saves Lives and Health Care Dollars
Toronto, Ontario--(Newsfile Corp. - March 3, 2026) - Oxygen therapy is a lifeline for people living with chronic lung diseases like pulmonary fibrosis. It reduces hospitalizations and improves quality of life. Yet across Canada, access to medically necessary oxygen therapy depends on where a person lives, inconsistent qualification criteria and, in some cases, one's ability to pay. The Canadian Pulmonary Fibrosis Foundation (CPFF) is calling on health authorities to designate supplemental oxy
Soins de santé et hôpitaux, Santé
2026-03-03 9:21 AM EST | Canadian Pulmonary Fibrosis Foundation
Jeffrey W. Sherman, MD, Joins DIMERx Board to Advance Next-Generation, Non-Addictive Pain Therapies
San Francisco, California--(Newsfile Corp. - March 3, 2026) - DIMERx, Inc. ("DIMERx" or "the Company"), is a clinical-stage biopharmaceutical company dedicated to addressing the public-health crisis of drug abuse and dependence, with a portfolio of first-in-class, dimer-based pain therapeutics engineered to deliver effective analgesia without the addiction liabilities of conventional opioids. The Company announced the appointment of Jeffrey W. Sherman, MD, FACP, to its Board of Directors. Dr.
Biotechnologies, Pharmaceutique, Santé
2026-03-03 9:00 AM EST | DIMERx INC.
BioHarvest Sciences to Participate in 38th Annual Roth Conference on March 22-24, 2026
British Columbia and Rehovot, Israel--(Newsfile Corp. - March 3, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that management has been invited to attend the 38th Annual Roth Conference taking place on March 22-24, 2026.
Biotechnologies, Pharmaceutique, Santé
2026-03-03 8:30 AM EST | BioHarvest Sciences Inc.
Red Light Holland Reports Third Quarter 2026 Results and Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - March 3, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based organization advancing a focused strategy within the legal psychedelic sector, centered on consensual data collection and research and development ("R&D") initiatives designed to expand naturally occurring drug development, understanding of psilocybin use and consumer experie
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-03-03 8:00 AM EST | Red Light Holland Corp.
Delota Reports Financial Results for the Three and Nine Months Ended December 31, 2025
Highlights Total revenue of $8.4 million for Q3 2026 Total System-Wide Revenue of $10.0 million for Q3 2026 30% gross profit margin for Q3 2026 Total revenue of $27.1 million for the Nine Months Ended 2026 Total System-Wide Revenue of $30.9 million for the Nine Months Ended 2026 33% gross profit margin for the Nine Months Ended 2026
Commerce de détail, Cannabis, Santé, Dispensaires de cannabis
2026-03-03 7:30 AM EST | Delota Corp.
Restart Life Announces Collaboration with University of Manitoba's Centre for Food Technology and Research
Vancouver, British Columbia--(Newsfile Corp. - March 3, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that, following the successful acquisition of Holy Crap Foods Inc., it has entered into a collaboration with the University of Manitoba's Richardson Centre for Food Technology and Research (RCFTR) to support a series of food-related scientific studies that will guide the Company's product development road
Technologies, Biotechnologies, Santé
2026-03-03 6:00 AM EST | Restart Life Sciences Corp.